Vorinostat for GVHD Prevention

A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

What's the purpose of the trial?

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
49
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Allogeneic Stem Cell Transplant is a type of stem cell transplant that utilizes a donor's pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
  • Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
  • Methotrexate is a chemotherapy medication that may be used in the treatment of many different cancers.
  • Mycophenolate Mofetil is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.
  • Tacrolimus is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.
  • Vorinostat is an HDAC inhibitor that is FDA approved for use in treating cutaneous T cell lymphoma (CTCL). It is being studied for use in several other indications.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Vorinostat

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.